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ABSTRACT
The antimetabolite 5-Fluorouracil (5-FU) is used in the treatment of various forms 
of cancer and has a complex mode of action. Despite 6 decades in clinical application 
the contribution of 5-FdUTP and dUTP [(5-F)dUTP] and 5-FUTP misincorporation into 
DNA and RNA respectively, for 5-FU-induced toxicity is still under debate.
This study investigates DNA replication defects induced by 5-FU treatment 
and how (5-F)dUTP accumulation contributes to this effect. We reveal that 5-FU 
treatment leads to extensive problems in DNA replication fork progression, causing 
accumulation of cells in S-phase, DNA damage and ultimately cell death. Interestingly, 
these effects can be reinforced by either depletion or inhibition of the deoxyuridine 
triphosphatase (dUTPase, also known as DUT), highlighting the importance of (5-F)
dUTP accumulation for cytotoxicity.
With this study, we not only extend the current understanding of the mechanism 
of action of 5-FU, but also contribute to the characterization of dUTPase inhibitors. 
We demonstrate that pharmacological inhibition of dUTPase is a promising approach 
WKDWPD\LPSURYHWKHHI¿FDF\RI)8WUHDWPHQWLQWKHFOLQLF
INTRODUCTION
Even after six decades, targeting thymidine 
synthesis is still one of the most successful strategies to 
treat cancer [1, 2]. Thymidylate synthase (TS) converts 
dUMP to dTMP, utilizing 5,10-methylenetetrahydrofolate 
(5,10-CH
2
THF) as methyl-donor. dTMP is the precursor 
for dTTP production, making this reaction essential 
for thymidine synthesis [3]. TS forms a homodimer, 
which contains both a substrate (dUMP), and a cofactor 
(5,10-CH
2
THF) binding pocket [4]. Inhibiting the function 
of TS can therefore be achieved by nucleobase- and 
nucleoside analogs (e.g. 5-Fluorouracil (5-FU) or FUdR), 
as well as antifolates (e.g. Pemetrexed) [3, 5].
7KH ÀXRURVXEVWLWXWHG XUDFLO DQDORJV DUH
metabolized to 5-FdUMP, which binds and thereby 
occupies the TS-substrate pocket [4]. Inhibition of TS 
leads to depletion of thymidine but also accumulation of 
the substrate dUMP, which is phosphorylated to dUTP. In 
addition, conversion of 5-FU to 5-FdUTP further elevates 
uracil levels. The increased dUTP/dTTP and 5-FdUTP/
dTTP ratios promote uracil misincorporation into DNA by 
DNA-polymerases [6]. Subsequent attempts of futile DNA 
repair eventually lead to cell death [610]. Besides DNA-
associated toxicity, incorporation of the 5-FU metabolite 
5-FUTP into RNA has been shown to contribute to cell 
death [1114]. However, the metabolism and working 
PHFKDQLVP RI ÀXRURS\ULPLGLQHV DUH FRPSOH[ DQG WKH
contribution of each of these components for toxicity is 
often debated.
Deoxyuridine triphosphatase (dUTPase, also 
known as DUT) circumvents high levels of uracil in 
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the biosynthetic pool by hydrolyzing dUTP to dUMP 
and pyrophosphate. This reaction additionally supplies 
TS with its substrate dUMP [15]. Despite the selective 
binding pocket of dUTPase, the 5-FU metabolite 5-FdUTP 
has been shown to be a substrate for this enzyme [16]. 
The physiological function of dUTPase is to reduce 
dUTP accumulation and prevent misincorporation of 
the non-canonical nucleotide into DNA. However, from 
a treatment perspective, this activity could hamper the 
therapeutic success of 5-FU.
Several studies have shown that dUTPase levels 
VLJQL¿FDQWO\ LQÀXHQFH 76EDVHG WUHDWPHQW UHVSRQVH
Ectopical overexpression of E. coli dUTPase induced 
resistance to FUdR in human cells [17]. In contrast, 
depletion of dUTPase increased response to FUdR and 
Pemetrexed [18, 19]. dUTPase expression also inversely 
correlated with sensitivity to TS inhibitor ZD9331 [20]. 
Moreover, in patient samples, high nuclear dUTPase 
expression was associated with both resistance to 5-FU 
therapy [21] and metastasis [22]. Interestingly, a dUTPase 
inhibitor was reported to sensitize cancer cells to 5-FU 
treatment in a xenograft setting [23].
Despite adjusting treatment regimens and improving 
TS-based therapies, a large number of patients still 
exhibit intrinsic or acquired treatment resistance [2]. 
)XUWKHU FODUL¿FDWLRQ RI WKH )8 PHFKDQLVP RI DFWLRQ
in combination with dUTPase inhibitors is required to 
improve the treatment outcome. Here, we demonstrate 
that 5-FU treatment induces DNA replication defects. 
Pharmacological inhibition and knockdown of dUTPase 
further augment 5-FU induced perturbations at the 
replication fork, DNA damage and cell death, highlighting 
the importance of 5-FdUTP and dUTP [(5-F)dUTP] and 
dUTPase for 5-FU-induced cytotoxicity.
RESULTS
dUTPase depletion increases cytotoxicity of 5-FU 
in SW620 colorectal cancer cells
To understand the importance and consequences 
of (5-F)dUTP accumulation during 5-FU treatment we 
depleted dUTPase in SW620 colorectal cancer cells 
using siRNA-mediated knockdown. Transfection with a 
G873DVH VSHFL¿F VL51$ VLG873DVH GHSOHWHG SURWHLQ
levels after 48 hours (Figure 1A and Supplementary 
Figure 7A). A non-targeting siRNA (siNon-t) control was 
compared to untransfected cells to rule out non-dUTPase 
related effects from the siRNA transfection.
dUTPase depleted and control cells were exposed 
to 5-FU for 48 hours and re-seeded to assess their 
ability to form colonies. Whereas dUTPase depletion 
E\LWVHOIKDGQRHIIHFWRQFHOOVXUYLYDOLWVLJQL¿FDQWO\
increased the cytotoxic effect of 5-FU, when compared 
to the untransfected or siNon-t transfected cells 
(Figure 1B).
To further understand the mechanism of toxicity, 
dUTPase-depleted and control cells were treated for 48 
hours with 5-FU and the cell cycle was analyzed by FACS. 
:KLOH)8WUHDWPHQWRIXSWRȝ0DFFXPXODWHGFHOOVLQ
S-phase, it had only minimal cytotoxic effects, indicated 
by a minor increase in the subG1 population (Figure 1C-
1D). dUTPase depletion, upon 5-FU treatment, increased 
the subG1 population already at the lowest dose of 
)8WHVWHGIURPWRȝ0RI)81RWDEO\
depletion of dUTPase by itself resulted in a small increase 
of subG1, S- and G2-phase cells and a reduction in the 
G1 population. No difference in the subG1 population 
was observed between the untransfected and siNon-t 
transfected cells (Supplementary Figure 1).
dUTPase depletion increases 5-FU-induced 
S-phase arrest of the cell cycle
To determine the number of S-phase cells in the cell 
cycle, we next measured EdU incorporation into DNA. As 
expected, 5-FU treatment alone increased the amount of 
cells in S-phase, as demonstrated by more incorporation 
of EdU into DNA (Figure 2A-2B). Interestingly, dUTPase 
depletion during the 5-FU treatment led to reduced amount 
of EdU being incorporated.
We further analyzed DNA replication using the 
alkaline DNA unwinding (ADU) technique (Figure 2C) 
[24]. In this assay, replicating forks are pulse labeled by 
incorporation of 3H thymidine, followed by a fresh media 
treatment. At increasing time points, DNA is unwound 
for about 60 kb by addition of an alkaline solution. The 
genome is subsequently fragmented into 3 kb pieces using 
ultrasonic treatment. This treatment creates a fraction of 
single stranded DNA (ssDNA) close to the replication 
fork and double stranded DNA (dsDNA) away from 
the fork. The radioactive label shifts from the ssDNA 
to the dsDNA fraction as the fork moves forward. The 
comparison of radioactivity in the ssDNA compared to 
the dsDNA fraction is therefore a measure of replication 
fork progression.
In line with the EdU data, 48 hours of 5-FU 
treatment led to increased incorporation of total 
radioactive thymidine at time zero compared to untreated 
cells, which can be explained by the increased amount 
of cells in S-phase (Figure 2D). Furthermore, dUTPase 
depletion reduced the total amount of thymidine 
incorporated, supporting the FACS analysis. Since 3H 
thymidine was used it would not require dUTPase activity 
to be introduced into DNA. Therefore, we conclude a true 
reduced fork rate following dUTPase treatment.
As time progressed and the replication fork 
proceeded, the radioactive signal moved from the ssDNA 
to the dsDNA fraction. When cells were treated with 
increasing concentrations of 5-FU, the ssDNA to dsDNA 
exchange was delayed in a dose-dependent manner, 
indicating reduced replication fork speed (Figure 2E). In 
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Figure 1: Depletion of dUTPase increases cytotoxicity of 5-FU in colorectal cancer cells. (A) Representative Western Blot 
DVVHVVLQJG873DVHH[SUHVVLRQDIWHUDQGKRXUVRIVL51$WUHDWPHQWXVLQJG873DVHVSHFL¿FVL51$VLG873DVHRUDQRQWDUJHWLQJ
VL51$FRQWUROVL1RQWȕ$FWLQZDVXVHGDVDORDGLQJFRQWURO(B) Clonogenic survival of dUTPase depleted cells compared to siNon-t 
transfected or untransfected controls, treated for 48 hours with increasing concentrations of 5-FU. Data shown as average ± SEM from two 
LQGHSHQGHQWH[SHULPHQWVSHUIRUPHGLQWULSOLFDWH6WDWLVWLFDOVLJQL¿FDQFHEHWZHHQXQWUDQVIHFWHGDQGVLG873DVHZDVGHWHUPLQHGE\XVLQJ
a two-tailed t-test. (C) FACS analysis highlighting cell cycle alterations induced by 5-FU treatment in sidUTPase and siNon-t transfected 
cells. After 48 hours of siRNA transfection, cells were re-seeded and, 24 hours later, treated for 48 hours with increasing concentrations of 
5-FU. DNA content was stained with PI and analyzed by FACS. Representative histograms are shown. Abbreviation: AU: arbitrary unit. 
(D)4XDQWL¿FDWLRQRIWKH)$&6H[SHULPHQWLQ)LJXUH&'DWDVKRZQDVDYHUDJH6(0IURPWZRLQGHSHQGHQWH[SHULPHQWV$EEUHYLDWLRQV
N: siNon-t, D: sidUTPase.
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Figure 2: 5-FU treatment accumulates cells in S-phase by decreasing replication fork progression, which can be 
accentuated by dUTPase depletion. (A) FACS analysis of incorporated EdU after the indicated treatments. After 72 hours of siRNA 
WUDQVIHFWLRQFHOOVZHUHWUHDWHGIRUKRXUVZLWKWKHLQGLFDWHGFRQFHQWUDWLRQRI)85HSOLFDWLRQZDVODEHOHGE\DGGLWLRQRIȝ0(G8
for 30 min, which was analyzed by FACS. EdU intensity is depicted on the y-axis and DNA content (To Pro intensity) on the x-axis. A 
representative experiment is shown. Abbreviation: AU: arbitrary unit. (B) Representative histograms displaying the EdU intensity over cell 
count (events) of the experiment shown in Figure 2A. Abbreviation: AU: arbitrary unit. (C) Schematic illustration of the ADU technique. 
(D) Total amount of 3H-thymidine incorporated within 30 min after 48 hours of 5-FU treatment in dUTPase depleted and control cells. 
Data shown as average ± SEM from two independent experiments. Data shown as average ± SEM from two independent experiments. (E) 
Replication fork progression, measured by the ADU technique, of SW620 cells treated with increasing concentrations of 5-FU for 48 hours. 
(F) Replication fork progression, measured by the ADU technique, in dUTPase depleted and control cells treated for 48 hours with 5-FU. 
For E-F: Percentage of radioactive label in the single stranded DNA (ssDNA) fraction compared to the total signal (ssDNA plus double 
stranded DNA) is depicted on the y-axis. Data shown as average ± SEM from two independent experiments.
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dUTPase depleted cells, an even slower exchange was 
observed, indicating on average slower DNA replication, 
compared to the siNon-t control (Figure 2F).
dUTPase depletion increases 5-FU-induced 
replication defects
While the ADU technique evaluates the average 
UHSOLFDWLRQ VSHHG LQ D GH¿QHG SRSXODWLRQ RI FHOOV WKH
EdU technique averages the EdU incorporation per cell. 
Nevertheless, these average values of replication speed 
FRXOGERWKLQGLFDWHDUHGXFHGQXPEHURI¿UHGUHSOLFDWLRQ
origins (with similar replication speed) or a reduction in 
fork progression. The speed of single replication forks 
FDQEHDQDO\]HGE\XVLQJWKH'1$¿EHUDVVD\LQZKLFK
successive incorporations of the thymidine analogues 
CldU and IdU into DNA is visualized by immunostaining 
(Figure 3A). Using this technique, we demonstrate that 
5-FU treatment reduces the replication fork speed, 
explaining the accumulation of cells in S-phase (Figure 
3A-3D). Depletion of dUTPase further decreases the DNA 
¿EHU OHQJWKV GHPRQVWUDWLQJ WKDW LQGLYLGXDO UHSOLFDWLRQ
forks are severely affected by lack of the dUMP substrate 
for TS.
Characterization of the dUTPase 
inhibitors 1 and 2
In order to study the effects of pharmacological 
dUTPase inhibition, two dUTPase inhibitors (compounds 
1 and 2, Figure 4A and 4B respectively) were synthesized 
as described in the Supplementary Materials and Methods 
(Supplementary Figure 2) [2527].
The potency of these inhibitors was assessed using 
an in vitro activity assay, in which dUTPase catalyzed 
the hydrolysis of dUTP to dUMP and pyrophosphate 
(PPi). The conversion of inorganic phosphate (Pi) from 
PPi was analyzed using the malachite green reagent. For 
WKLVSXUSRVHG873DVHZDVH[SUHVVHGDQGSXUL¿HGIURP
bacterial lysates (Supplementary Figure 3A) and its 
activity was assessed with dUTP and 5-FdUTP (6.6 and 
ȝ0IRUPHG33LSHUVHFRQGSHUȝ0HQ]\PHVLPLODUWR
previously reported data) (Supplementary Figure 3B) [28]. 
Compound 1 shows an IC
50
 of 740 nM while compound 2 
H[KLELWVDQDSSUR[LPDWHO\IROGKLJKHUHI¿FDF\ZLWKDQ
IC
50
 of 25 nM (Figure 4C). In addition, these compounds 
showed high selectivity in a pannel of various nucleoside 
triphosphate pyrophosphatase or phosphohydrolase 
enzymes tested (Supplementary Figure 4).
Computational docking predicts the putative binding 
modes for compounds 1 and 2 in the substrate binding 
pocket of dUTPase (Figure 4D and Supplementary 
Materials and Methods). For both compounds, the docking 
with the lowest Glide SP scores (-8.23 and -7.13 kcal/
mol, respectively) had their uracil moieties inserted deep 
into the uracil binding pocket and displayed the same 
H-bonding patterns as described for other uracil-based 
ligands, interacting with Gly99, Gly110 and a conserved 
water molecule that bridges uracil, Gly97 and Val112. The 
ÀH[LEOHVLGHFKDLQVRIERWKOLJDQGVKDGDGRSWHG8VKDSHG
conformations with one of the aryl group folding back 
over the uracil moiety. The amide linker of inhibitor 1 and 
sulfonamide linker of compound 2 are facing the solvent, 
while the terminal cyclopentyl moiety of compound 2 
partially occupies the same region as the second terminal 
phenyl group of compound 1 7KH EHQ]\OLF ĮPHWK\O
group of inhibitor 2 occupied the same region as the 
proline ring of compound 1, providing a hypothesis for 
the observed stereochemical preference displayed by 
structurally closely related representatives of these two 
chemical series [29, 30].
dUTPase inhibitors sensitize colorectal cancer 
cells to 5-FU treatment
We next analyzed whether pharmacological 
inhibition of dUTPase, using compounds 1 or 2, is a 
SRWHQWLDOVWUDWHJ\WRLQFUHDVHWKHHI¿FDF\RI)8&HOO
survival was assessed after 72 hours of co-treatment using 
WKHUHVD]XULQDVVD\,QKLELWLRQRIG873DVHVLJQL¿FDQWO\
increased the cytotoxicity of the 5-FU treatment (Figure 
5A and Supplementary Figure 5A for compounds 2 and 
1, respectively). In line with protein depletion, dUTPase 
inhibition alone did not induce cellular toxicity at the 
concentrations and time points tested. Importantly, the 
toxicity induced by 2 upon 5-FU treatment was rescued 
by addition of thymidine (Figure 5B). In addition, the 
cervix cancer cell line HeLa showed increased sensitivity 
to 5-FU by addition of compounds 1 or 2 and to a minor 
extend a slight effect is observed with the cell line TOV-
112D (ovary origin) (Figure 5C). On the contrary, the 
osteosarcoma cell line U2OS showed no increase in 5-FU 
toxicity when dUTPase was inhibited. The sensitivity did 
only partially correlate with dUTPase expression levels, as 
both HeLa and SW620 cells exhibit increased sensitivity 
to 5-FU upon addition of compounds 1 or 2, but only Hela 
cells show high expression levels of dUTPase (Figure 5D 
and Supplementary Figure 7B). These data demonstrate 
a variability in potentiation of 5-FU toxicity in different 
cancer cell lines.
dUTPase inhibitors increase 5-FU induced 
replication defects and DNA damage
We then studied the effects of the dUTPase inhibitors 
on 5-FU-induced S-phase arrest by co-treating cells for 48 
hours with inhibitor 2 and 5-FU and subsequent labelling 
ZLWK(G8,QFHOOVWUHDWHGZLWKȝ0RI)8LQKLELWLRQ
of dUTPase by compound 2 further reduced the amount of 
incorporated EdU in a dose dependent manner (Figure 6A-
%'1$¿EHUH[SHULPHQWVUHYHDOHGWKDWWKHUHGXFHG(G8
incorporation also correlated with decreased replication 
Oncotarget23718www.impactjournals.com/oncotarget
fork progression, supporting the data previously obtained 
by dUTPase knockdown experiments (Figure 6C-6E and 
Supplementary Figure 5B-5D).
6WDLQLQJRISKRVSKRU\ODWHGKLVWRQH+$;Ȗ+$;
is commonly used to visualize DNA damage in association 
with replication fork stress [31]. Here, we determine 
Ȗ+$; IRFL IRUPDWLRQ E\ DXWRPDWHG PLFURVFRS\
following treatment of cells for 72 hours with 5-FU, and 
demonstrate that addition of compound 1 or 2 to the 5-FU 
treatment further increased DNA damage (Supplementary 
)LJXUH1RLQFUHDVHLQȖ+$;IRFLFRXOGEHGHWHFWHGLQ
cells treated with the dUTPase inhibitors alone.
dUTPase inhibition likely leads to accumulation of 
dUTP and 5-FdUTP and subsequent misincorporation into 
DNA. To test this hypothesis, we analyzed dU and 5-FdU 
levels in DNA using mass spectrometry. While 5-FU 
treatment alone had only minimal effects on the dU levels 
LQ'1$VLPXOWDQHRXVG873DVHLQKLELWLRQVLJQL¿FDQWO\
raised the amount of dU incorporation into DNA (Figure 
6F). Following co-treatment of compound 2 and 5-FU, 
some low levels of 5-FdU in DNA were observed but were 
WRRFORVHWRGHWHFWLRQOLPLWWRPDNHDQ\¿UPFRQFOXVLRQ
(data not shown). No 5-FdU in DNA was detected in DNA 
from single-treated cells (data not shown).
Figure 3: 5-FU treatment decreases replication fork speed, which is enhanced by dUTPase depletion. (A) Schematic 
LOOXVWUDWLRQ RI &OG8 UHG DQG ,G8 JUHHQ ODEHOLQJ GXULQJ WKH '1$ ¿EHU DVVD\ (B) 5HSUHVHQWDWLYH LPDJHV RI '1$ UHSOLFDWLRQ ¿EHUV
from dUTPase depleted and control cells treated with the indicated concentration of 5-FU. (C) Average fork speed during IdU labeling in 
dUTPase depleted and control cells after 48 hours of 5-FU treatment. Data shown as average ± SEM from three independent experiments. 
Abbreviations: N: siNon-t, D: sidUTPase. (D)'LVWULEXWLRQRI,G8ODEHOHG¿EHUOHQJWKLQG873DVHGHSOHWHGDQGFRQWUROFHOOV'DWDVKRZQ
as average ± SEM from three independent experiments.
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Figure 4: Compounds 1 and 2 inhibit dUTPase activity. Chemical structures of the dUTPase inhibitors 1 (A) and 2 (B) (C) Potency 
of compounds 1 and 2 was assessed by malachite green assay, using dUTP as a substrate. Percentage activity was calculated compared 
to DMSO treated control. Inhibition curves shown are representative curves of two independent inhibition experiments performed using 
duplicate measurements. IC
50
 values displayed in (A) and (B) were determined from two independent experiments performed in duplicate 
and are shown as average ± SD. (D) Superposition of the top-ranked docking poses of compounds 1 (blue sticks) and 2 (orange sticks). The 
different monomers of the protein are rendered as green, cyan and magenta cartoons. H-bonds are shown as yellow dotted lines.
Oncotarget23720www.impactjournals.com/oncotarget
DISCUSSION
(YHQ\HDUVDIWHUWKH¿UVWV\QWKHVLVRIDQWLIRODWHV
DQG ÀXRURS\ULPLGLQHV WKH FRPSOH[ PHFKDQLVP RI
action is still debated [32, 33]. Initially, depletion of 
thymidine was thought to be the main cause of 5-FU 
induced toxicity [34, 35]. Many studies have in addition 
highlighted the importance of elevated levels of both 
XUDFLODQGÀXRURXUDFLODQGWKHLUPLVLQFRUSRUDWLRQLQWR
DNA [6, 36, 37]. More recently, incorporation of 5-FUTP 
into RNA and its associated transcription defects have 
been considered as the main cause of cell death [38]. 
Figure 5: The dUTPase inhibitors sensitize cells to 5-FU treatment. (A) Resazurin experiment assessing the viability of SW620 
cells co-treated with 5-FU and the dUTPase inhibitor 2 at the indicated concentrations for 72 hours. Values were normalized against the no-
DMSO control (-). Data shown as average ± SEM from three independent experiments performed in duplicate. (B) Resazurin experiment 
analyzing cellular viability after 72 hours of co-treatment with 5-FU and compound 2ȝ0LQFRPELQDWLRQZLWKWK\PLGLQHȝ0
Values were normalized against the DMSO control. Data shown as average ± SEM from at least four independent experiments performed 
in duplicate. (C)9LDELOLW\RI+H/D729'DQG826FHOOVWUHDWHGZLWKȝ0RIFRPSRXQG1 or 2 and increasing concentrations of 
5-FU. After 72 hours of the indicated treatment cell viability was analyzed by Resazurin. Data shown as average ± SEM from at least three 
independent experiments performed in duplicate. (D):HVWHUQ%ORWDQDO\]LQJWKHG873DVHOHYHOVLQWKHLQGLFDWHGFHOOOLQHVȕ$FWLQZDV
used as a loading control.
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)LJXUH 7KH G873DVH LQKLELWRUV LQFUHDVH )8 HI¿FDF\ E\ LQFUHDVLQJ G8 LQ '1$ DQG UHGXFLQJ UHSOLFDWLRQ IRUN
speed. (A))$&6DQDO\VHVPHDVXULQJWKH(G8LQFRUSRUDWLRQRI6:FHOOVWUHDWHGIRUKRXUVZLWKȝ0RI)8LQFRPELQDWLRQZLWK
increasing doses of compound 2. EdU intensity is depicted on the y-axis and DNA content (To Pro intensity) on the x-axis. A representative 
experiment is shown. (B) Representative histograms displaying the EdU intensity of the experiment shown in Figure 6A. The intensity of 
the PI staining is depicted on the x-axis and events (cell count) on the y-axis. Abbreviation: AU: arbitrary unit. (C) Representative images 
RI'1$UHSOLFDWLRQIRUNVIURPFHOOVWUHDWHGZLWKWKHLQGLFDWHGFRQFHQWUDWLRQRI)8RU'062LQFRPELQDWLRQZLWKȝ0RIFRPSRXQG
2 or a DMSO control for 48 hours. (D) Average fork speed during IdU labelling of cells treated as described in Figure 6C. Data shown 
as average ± SEM from two independent experiments. (E)'LVWULEXWLRQRI,G8ODEHOOHG¿EHUOHQJWKRIWKHH[SHULPHQWVKRZQLQ)LJXUH
6C6D. Data shown as average ± SEM from two independent experiments. (F) dU content in SW620 cells treated for 48 hours with the 
indicated concentration of 5-FU in combination with compound 2 or DMSO, by mass spectrometry. Data shown as average ± SEM from 
three independent experiments.
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Studying the mechanism of action of 5-FU is necessary 
to understand and overcome frequently observed drug 
resistance and ultimately improve patient care.
Here, we investigated the DNA replication defects 
induced by 5-FU treatment and the importance of 
5-FdUTP accumulation for this effect. By analyzing 
EdU incorporation into DNA, we observed that 5-FU 
treatment leads to accumulation of cells in the S-phase of 
WKHFHOOF\FOH$'8H[SHULPHQWVDQG'1$¿EHUDQDO\VHV
demonstrated slower DNA replication fork progression 
upon 5-FU treatment, which are in agreement with low 
dTTP levels generated by TS inhibition. Hence, our 
conclusion is that reduced replication fork speed by 
combination treatment of dUTPase inhibitors/siRNA and 
5-FU is a result of even lower levels of dTTP, caused by 
low substrate dUMP levels (by dUTPase loss) and low 
TS activity (by 5-FU treatment). Uracil analogues (EdU, 
&OG8,G8ZHUHXVHGIRUWKH'1$¿EHUDQGFHOOF\FOH
experiments. Since these uracil analogues are already 
PRGL¿HG RQ WKH ¶SRVLWLRQ WKH\ OLNHO\ GR QRW QHHG
dUTPase activity to be incorporated into DNA as also 
suggested by the fact that we observed no decrease in the 
LQWHQVLW\RI¿EHUVIROORZLQJG873DVHLQKLELWLRQRUVL51$
treatments.
Interestingly, protein depletion and pharmacological 
inhibition of the nucleotide triphosphatase dUTPase 
further augmented the amount of uracil in DNA, DNA 
replication defects, DNA damage and cytotoxicity 
of 5-FU, highlighting the importance of (5-F)dUTP 
accumulation for cytotoxicity. However, one should 
keep in mind that the 5-FU metabolism involves various 
enzymes and intermediate species and that the mode of 
toxicity is most likely multifaceted and dependent on the 
molecular makeup of the cell.
Despite this complexity, a number of studies have 
VKRZQ WKDW G873DVH OHYHOV VLJQL¿FDQWO\ LQÀXHQFH WKH
HI¿FDF\RI)8DQGRWKHU76EDVHG WKHUDSLHV >±
22, 39]. These studies have often used siRNA mediated 
dUTPase depletion. However, in certain situations a 
discrepancy between protein inhibition and depletion can 
be observed. Here, we showed that inhibiting dUTPase 
with small molecules leads to comparable effects as 
protein depletion by siRNA.
Furthermore, we show that inhibiting dUTPase 
activity, both by siRNA and pharmacological inhibition, 
does not lead to severe toxicity when used as a mono-
WUHDWPHQW$IDYRUDEOHVDIHW\SUR¿OHZDVDOVRFRQ¿UPHG
by the phase I clinical trial of the dUTPase inhibitor TAS-
114 [40].
Importantly, tumors were found to have dysregulated 
dUTPase expression and high nuclear dUTPase expression 
correlated with therapy resistance, shorter time to 
progression and shorter overall survival [21]. With this 
study, we further elucidate the mechanism of 5-FU-
induced toxicity by investigating DNA replication defects. 
Inhibiting dUTPase activity by siRNA or inhibitors 
VLJQL¿FDQWO\DXJPHQWHG)8LQGXFHGUHSOLFDWLRQGHIHFWV
and toxicity, highlighting the contribution of (5-F)dUTP 
to toxicity. These results demonstrate the high potential of 
dUTPase inhibitors to improve current TS therapies.
MATERIALS AND METHODS
Cell culture
SW620, HeLa, TOV-112D and U2OS cells were 
cultured in 37 °C with 5% CO
2
 using DMEM (Life 
Technologies), supplemented with fetal calf serum 
 SHQLFLOOLQ  8P/ DQG VWUHSWRP\FLQ  ȝJ
mL). Mycoplasma contamination was assessed using 
the MycoAlertTM Mycoplasma Detection Kit (Lonza). 
Thymidine (Sigma-Aldrich) was diluted in H
2
O, 5-FU 
(Sigma-Aldrich) was diluted in DMSO to 200 mM, while 
compounds 1 and 2 were dissolved in DMSO to 10 mM. 
DMSO concentrations were adjusted to equal levels in all 
treatments.
RNAi transfection
siRNA was transfected using INTERFERin® 
DV VXJJHVWHG E\ WKH PDQXIDFWXUHU¶V LQVWUXFWLRQV
(polyplus transfectionTM). Oligonucleotides targeting 
all three isoforms of dUTPase (sense strand: 
¶&**$&$88&$*$8$*&*&877¶ DQWLVHQVH
VWUDQG¶$*&*&8$8&8*$$8*8&&*77¶UHIHUUHG
to as sidUTPase) and the All-stars negative control 
(referred to as siNon-t) were obtained from Qiagen and 
WUDQVIHFWHGWRD¿QDOFRQFHQWUDWLRQRIQ0&HOOVZHUH
siRNA transfected for 48 hours, re-seeded and incubated 
overnight to achieve attachment. Additional treatment was 
performed as indicated in the different sections.
Western blot analysis
Cells were lysed with RIPA buffer (150 mM NaCl, 
1.0% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 
50 mM Tris-HCl (pH 8.0), complete protease inhibitor 
cocktail (Roche) and phosphatase inhibitors (Phosphatase 
Inhibitor cocktail, Life Technologies)). After sonication, 
the debris was removed by centrifugation. Protein 
concentration was assessed using the Pierce BCA 
Protein Assay Kit (Thermo Fisher). Lysates, supplemented 
with 4x Laemmli buffer (Bio-Rad) containing 
2-mercaptoethanol, were heated to 95 °C for 5 min. 
Proteins were separated with Mini-PROTEAN TGXTM 
gels (Bio-Rad) using Tris/Glycine/SDS running buffer 
%LR5DG DQG WUDQVIHUUHG WR D  ȝP QLWURFHOOXORVH
membrane (Bio-Rad) with the Trans-Blot TurboTM Transfer 
Starter System (Bio-Rad). Membranes were blocked with 
Odyssey Blocking Buffer (LI-COR, 1:1 in PBS) before the 
SULPDU\DQWLERGLHVDQWLG873DVHUDWDNLQGJLIW
IURP3URI*UlVVHU>@DQGȕ$FWLQ$EFDPDE
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were added overnight at 4 °C. IRDye® 800CW secondary 
antibodies anti-rat and anti-mouse (LI-COR) were added 
for 1 hour. Fluorescence was visualized using an Odyssey® 
Fc Imager and Image Studio Software (LI-COR). The 
VSHFL¿FLW\ RI WKH DQWLG873DVH DQWLERG\ LV VKRZQ LQ
Supplementary Figure 7.
Clonogenic survival assay
After siRNA transfection, the indicated 
concentration of 5-FU was added for 48 hours, followed 
by a 24 hours recovery period with fresh media. 200 cells 
were re-seeded onto petri dishes in triplicate and incubated 
IRU  GD\V &RORQLHV ZHUH ¿[HG DQG YLVXDOL]HG XVLQJ
methylene blue (4 g/L) in methanol and then assessed 
by eye. Surviving fractions were calculated by averaging 
the triplicate values and normalizing these against the 
untransfected DMSO control.
Propidium iodine (PI) FACS analysis
Following the indicated treatment, the cells and the 
PHGLDZHUH FROOHFWHG6DPSOHVZHUHZDVKHGDQG¿[HG
by freezing cells in 70% ethanol. After two PBS washes, 
P/3,VROXWLRQȝJP/3,6LJPDDQGȝJP/
51DVH$7KHUPR)LVKHU6FLHQWL¿FLQ3%6ZDVDGGHG
for 20 min. PI intensity was measured on a FACSCalibur 
(Becton Dickinson) and the cell cycle was analyzed using 
WinMDI 2.9.
5-ethynyl-2-deoxyuridine (EdU) and To Pro 
FACS analyses
To assess replication, cells were pulse labeled using 1 
ȝ0(G8IRUPLQ7KH&OLFNL7® EdU Alexa Fluor® 488 
Imaging Kit (Molecular Probes) was used as described in the 
PDQXIDFWXUHU¶VPDQXDO'1$ZDVFRXQWHUVWDLQHGZLWKȝJ
mL To Pro (Molecular Probes). EdU and To Pro intensities 
were measured on a FACSCalibur (Becton Dickinson) and 
analyzed using WinMDI 2.9 and Cytobank.
Alkaline DNA unwinding (ADU) technique
The method was performed as described by 
Johansson et al. >@ %ULHÀ\ FHOOV ZHUH SXOVHODEHOHG
with 3+WK\PLGLQHN%TP/*(+HDOWKFDUHIRU
min. Cells were washed and incubated in media plus the 
LQGLFDWHG WUHDWPHQW IRU WKH VSHFL¿HG WLPHSRLQWV ,FH
cold 0.03 M of NaOH in 0.15 M of NaCl was added for 
30 min incubation on ice and in darkness. Addition of 
1 mL of 0.02 M NaH
2
PO
4
 stopped the unwinding. The 
DNA was fragmented by ultrasonic treatment for 15 
VHFRQGV % VRQL¿HU ZLWK PLFURWLS %UDQVRQ 6'6
ZDVDGGHGWRD¿QDOFRQFHQWUDWLRQRIDQGVDPSOHV
were frozen overnight. After a 1:1 dilution with distilled 
water, the samples were added to hydroxyapatite columns 
mounted in an aluminum block maintained at 60 °C. The 
columns were washed with 0.5 M potassium phosphate 
before the single stranded and then double stranded DNA 
fractions were respectively eluted with 0.1 M and 0.25 M 
potassium phosphate buffer. Radioactivity was assessed 
on a RackBeta scintillation counter. The amount of single 
stranded DNA was compared to the total labeled DNA.
'1$¿EHUWHFKQLTXH
7KH'1$¿EHU WHFKQLTXHZDV VLPLODUO\SHUIRUPHG
as described by Groth et al. [43]. Cells were treated as 
LQGLFDWHGEHIRUHFKORUR¶GHR[\XULGLQH&OG8ȝ0
Sigma) was added for 40 min followed by 40 min incubation 
ZLWKLRGR¶GHR[\XULGLQH,G8ȝ06LJPDZLWK
the indicated treatment present. Cells were scraped in ice-
cold PBS. Unlabeled and labeled cells were mixed in equal 
SURSRUWLRQVȝ/RIWKHFHOOVXVSHQVLRQZHUHPL[HGZLWK
ȝ/VSUHDGLQJEXIIHUP07ULV+&OS+P0
EDTA and 0.5% SDS) on microscopy slides (SuperFrost®, 
Menzel Gläser, VWR). After 8 min, the slides were tilted 
WRVSUHDGWKH'1$DQGWKHQ¿[HGE\LQFXEDWLRQLQ0H2+
AcOH (3:1) overnight at 4 °C. Samples were denatured in 
0+&OIRUKRXUDQGXQVSHFL¿FELQGLQJZDVEORFNHG
using PBS containing 1% BSA and 0.1% Tween20. 
For immunodetection of CldU and IdU, the slides were 
incubated with monoclonal rat anti-BrdU Ab (Clone BU1/75 
,&52[IRUG%LRWHFKQRORJLHVDQGPRQRFORQDOPRXVH
DQWL%UG8 $E &ORQH % %HFWRQ 'LFNLQVRQ 
Anti-rat Alexa Fluor® 555 and anti-mouse Alexa Fluor® 488 
LQEORFNLQJVROXWLRQ/LIH7HFKQRORJLHVZHUHXVHGDV
secondary antibodies. Images of coded samples were taken 
on a Zeiss LSM 510 or 780 inverted confocal microscope. 
Fiber length was measured using the ImageJ software. 1 
ȝPZDVFRQYHUWHGWRNLOREDVHSDLUV$WOHDVWIRUNV
were analyzed per sample.
Resazurin survival assay
FHOOVZHUHVHHGHGLQȝ/PHGLXPSHUZHOO
LQWRZHOOSODWHVKRXUVODWHUȝ/RIFRPSRXQG1 or 
2ZDVDGGHGWRUHDFKD¿QDOFRQFHQWUDWLRQRIWKHLQGLFDWHG
GRVHDIWHUDGGLWLRQRIȝ/)8VWRFN$IWHUKRXUV
ȝ/RIWKH)8VWRFNZDVDGGHGWRHDFKZHOOWRUHDFK
the indicated concentration. After 72 hours, resazurin 
ZDVDGGHGWRD¿QDOFRQFHQWUDWLRQRIȝJP/DQGWKH
cells were incubated 3 hours. Fluorescence intensity was 
measured at 544/590 nm (Ex/Em). Relative survival of 
the cells was calculated by subtracting the background 
ÀXRUHVFHQFH DYHUDJLQJ GXSOLFDWH PHDVXUHPHQWV DQG
normalizing the value to the untreated well.
4XDQWL¿FDWLRQRIPRGL¿HGEDVHVLQJHQRPLF'1$
'1$ IRU QXFOHRVLGH TXDQWL¿FDWLRQ ZDV LVRODWHG
by phenol:chloroform:isoamyl alcohol extraction as 
previously described [44]. Cells were lysed by passing 
through 21G and 23G syringe needles and subsequent 
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incubation at 37 °C for 1 h with 1000 RPM shaking in 
a buffer containing 10 mM Tris-HCl (pH 8.0), 10 mM 
NaCl, 1% SDS, 100 mM DTT, 0.1 mg/mL proteinase 
K (Worthington Biochemical), 0.1 mg/mL RNase A 
6LJPD$OGULFKȝ0WHWUDK\GURXULGLQH7+80HUFN
Millipore). DNA was subsequently extracted from the 
lysates with 25:24:1 phenol:chloroform:isoamyl alcohol, 
followed by two washes with 24:1 chloroform:isoamyl 
alcohol and isopropanol precipitation using 10 M 
ammonium acetate to precipitate the DNA. RNA and free 
nucleotides were then removed from the DNA samples 
E\WUHDWPHQWZLWKȝJ51DVH$LQP0DPPRQLXP
bicarbonate (pH 7.0), 10 mM MgCl
2
 for 30 min at 37 °C, 
followed by a subsequent isopropanol precipitation.
Next, the DNA samples were hydrolyzed and 
dephosphorylated to single nucleosides as previously 
described [44]. DNA was hydrolyzed to nucleosides by 
treatment with 0.8 U Nuclease P1 (Sigma-Aldrich), 80 
U Benzonase (Santa Cruz Biotechnology), and 7.5 U 
$QWDUFWLF3KRVSKDWDVH1HZ(QJODQG%LRODEVLQȝ/
reactions containing 10 mM ammonium acetate (pH 5.5), 
1 mM MgCl
2
, 0.1 mM ZnCl
2
DQGȝ07+8IRUPLQ
at 37 °C. Enzymes were then precipitated and removed 
from the reactions by adding three volumes of ice-cold 
acetonitrile to the reactions, incubating for 10 min on 
ice, centrifugation at 16,100 rcf for 30 min at 4 °C. The 
supernatants were transferred to new tubes and lyophilized 
XQWLO GU\ )RU ÀXRURGHR[\XULGLQH )G8 
8 DONDOLQH SKRVSKDWDVH 6LJPD$OGULFK DQG  ȝ0
Deferoxamine mesylate (Santa Cruz Biotechnology) were 
used instead of Antarctic Phosphatase and THU.
To separate dU from dC, the samples were 
redissolved in water and fractionated on an Agilent 
1100 HPLC system (with a UV detector set to 260 nm 
to identify the canonical nucleosides) and a mixed mode 
3ULPHVHSFROXPQPP[PPȝP6LH/&
NHSWDW&XVLQJDÀRZUDWHRIP/PLQDQGZDWHU
and acetonitrile as mobile phase, each containing 0.1% 
formic acid, as the mobile phase. The 12-min-long HPLC 
gradient was as follows: 5% acetonitrile for 30 s, ramp 
to 35% acetonitrile by 1.5 min to 2.5 min, and return to 
5% acetonitrile by 2.51 min. The dU-containing fractions 
were collected from 1.6-1.7 min and vacuum centrifuged 
until dry. Samples were not pre-fractionated for 5-FdU 
analysis. The pellets were redissolved in water and 
analysed by LCMS/MS using a reverse phase column (2.1 
PP[PPȝP(FOLSVH3OXV&55+'$JLOHQW
7HFKQRORJLHVNHSWDW&ZLWKDÀRZUDWHRIP/
PLQRQD,Q¿QLW\,,+3/&FRXSOHGWRD7ULSOH
Quadrupole mass spectrometer with an electrospray ion 
source (Agilent Technologies). Water and methanol were 
used as the mobile phase, each containing 0.1% formic 
acid. The 13-min-long HPLC gradient was as follows: 5% 
methanol for 3 min, ramp to 13% methanol by 3.5 min, 
ramp to 17% methanol by 5.5 min to 7 min, and return 
to 5% methanol by 8 min. Analysis was performed in 
positive ionization multiple reaction monitoring mode, 
XVLQJ WKH PDVV WUDQVLWLRQV  ĺ   ĺ
 DQG  ĺ  IRU GHR[\XULGLQH G8
13C15N
2
-dUrd, 5-FdU, respectively.
The Supplementary Materials and Methods contain 
additional information regarding the expression and 
SXUL¿FDWLRQRIKXPDQUHFRPELQDQWG873DVHWKHG873DVH
activity and inhibition assay, the detailed synthetic 
route for dUTPase inhibitors 1 and 2, as well as their 
molecular dockings with dUTPase, and the analysis of 
phosphorylated H2A.X.
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